- Novo Nordisk's oral semaglutide (Rybelsus) is being aggressively reformulated to close the efficacy gap with injectable versions, with Phase III data expected mid-2026 using an enhanced absorption technology.
- Eli Lilly's oral tirzepatide candidate entered Phase II with results suggesting 8-11% weight loss at 26 weeks, meaningful but still trailing injectable benchmarks by approximately 6 percentage points.
- Pfizer has re-entered the oral GLP-1 race following the 2023 discontinuation of danuglipron, pursuing a new candidate with a modified dosing strategy designed to address prior GI tolerability failures.
- The oral peptide delivery space has attracted more than $3.2 billion in licensing and partnership deals in the first four months of 2026, reflecting the size of the commercial prize at stake.
- Clinical operations hiring for oral GLP-1 programs is running 30-40% ahead of prior year levels, with Phase II/III trial management and regulatory affairs roles in highest demand.
Why Oral Delivery Is the Industry's Top Priority
The injectable GLP-1 market has been a commercial phenomenon, semaglutide and tirzepatide together generated more than $30 billion in combined global revenue in 2025, but the clinical reality is that a meaningful fraction of patients who would benefit from these medications never start them. The barriers are familiar: needle aversion, the logistical complexity of refrigerated products, and the social visibility of self-injection in public settings.
Oral formulation eliminates all of these barriers. If an oral GLP-1 can deliver comparable efficacy to injectable versions, the addressable patient population expands dramatically. Multiple independent market analyses project that an oral product matching injectable performance would roughly double the commercial ceiling for GLP-1 receptor agonists.
The technical challenge is substantial. GLP-1 peptides are inherently poor candidates for oral delivery. The gastrointestinal environment is physiologically hostile to intact peptide absorption, proteolytic enzymes, the acid environment of the stomach, and the gut wall's permeability characteristics all work against the peptide reaching systemic circulation in meaningful quantities. Current oral semaglutide, despite its commercial success as a Type 2 diabetes treatment, achieves bioavailability of less than 1% of the injectable form.
The estimated annual revenue difference between an oral GLP-1 achieving 90% of injectable efficacy versus the current oral semaglutide 14mg profile is approximately $8-12 billion across the U.S. market alone, based on current market penetration projections and average selling price assumptions.
Novo Nordisk's COMET Program
Novo Nordisk has the most advanced oral semaglutide franchise and is building from a position of commercial strength. The COMET program represents the company's effort to close the efficacy gap between its oral and injectable semaglutide products using absorption-enhancement technology.
The core technology in COMET uses a proprietary co-administration strategy with a modified sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC) formulation that has been optimized for higher local concentrations at the gastric mucosa. Early clinical data from the Phase IIb COMET program, presented at a diabetes congress in March 2026, showed average weight reduction of 14.8% at 52 weeks, a meaningful improvement over the 10-15% range seen with the current Rybelsus formulation and approaching the lower end of injectable semaglutide outcomes.
The regulatory path for COMET is under active discussion with FDA. Novo Nordisk is pursuing a supplemental NDA strategy for the obesity indication, with the absorption enhancement technology positioned as a manufacturing process improvement rather than a new drug entity. If FDA accepts this framing, the development timeline could be materially shorter than a new NDA pathway.
Staffing Implications at Novo Nordisk
Novo Nordisk's U.S. operations have posted more than 200 positions in the past 90 days related to oral peptide programs, including roles in clinical development, regulatory affairs, formulation science, and commercial launch planning. The company has been particularly active in recruiting from academic oral drug delivery programs and from competitors' formulation teams.
Eli Lilly's Orforglipron and Oral Tirzepatide Programs
Eli Lilly is pursuing oral delivery through two distinct approaches. Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist, technically outside the peptide space but competing for the same clinical indication, while a separately disclosed program is pursuing a true oral tirzepatide formulation.
The oral tirzepatide program is the more strategically significant from a peptide therapeutics perspective. Tirzepatide's dual GIP/GLP-1 receptor agonism has demonstrated superior weight loss outcomes compared to GLP-1-only approaches in head-to-head clinical data. If those outcomes can be replicated in an oral format, Lilly would have a potentially dominant product.
Phase II data for oral tirzepatide presented in April 2026 showed that the median weight loss at week 26 reached 9.2% in the highest dose cohort. While this trails injectable tirzepatide at the same timepoint, the dose-escalation design suggests that further optimization of the absorption technology could narrow the gap materially.
Lilly's combined oral GLP-1 pipeline R&D spending is estimated at $1.4-1.8 billion for fiscal 2026, according to company guidance and analyst estimates, representing approximately 15% of total R&D expenditure.
Pfizer's Second Attempt: Lessons From Danuglipron
Pfizer's exit from the oral GLP-1 race following the discontinuation of danuglipron in 2023, driven by GI adverse events in Phase II, was widely read as a setback for the small-molecule approach to GLP-1 oral delivery. The company's return with a new candidate in early 2026 signals a conviction that the tolerability problem is solvable with modified dosing strategies.
The new Pfizer candidate uses a significantly lower starting dose with a slower titration schedule than danuglipron. Preclinical and Phase I data suggest that the GI adverse event profile is meaningfully improved when plasma concentration rise is managed carefully, which the new dosing algorithm achieves.
The Phase II program initiated in February 2026 is designed with the GI tolerability issue as a primary endpoint alongside efficacy, reflecting the company's determination not to repeat the danuglipron experience. Results are expected in late Q4 2026 or early 2027.
The Broader Competitive Landscape
Beyond the three largest programs, the oral GLP-1 space has attracted a range of emerging entrants. Structure Therapeutics, Viking Therapeutics, and Terns Pharmaceuticals each have oral GLP-1 or GLP-1-adjacent programs in mid-stage development. The activity among smaller biotech companies reflects both the commercial opportunity and the availability of partnership capital for credible oral delivery assets.
Several of these smaller programs are built around novel permeation enhancement technologies, approaches using tight junction modulators, nanoparticle encapsulation, or mucoadhesive carriers that differ fundamentally from the SNAC technology underpinning current oral semaglutide. If any of these alternative approaches demonstrates superior bioavailability at scale, it could create licensing opportunities that reshape the competitive hierarchy.
Clinical Operations Hiring Trends
The volume of oral GLP-1 programs running concurrently in 2026 is creating significant demand for specialized clinical talent. Clinical research associates (CRAs) with GLP-1 or metabolic disease trial experience command meaningful salary premiums over colleagues without this background. Clinical project managers for Phase II/III GLP-1 studies at large pharma are seeing total compensation packages 20-25% above similar-scope oncology programs, reflecting the priority these programs hold in pipeline investment.
Regulatory affairs specialists with FDA Division of Diabetes, Lipid Disorders, and Obesity (DDLO) interaction experience are among the most sought-after hires in the sector. Companies are offering sign-on bonuses of $30,000-$75,000 for candidates with prior DDLO advisory meeting experience relevant to oral peptide programs.
The oral formulation science specialty, a relatively narrow sub-discipline combining peptide chemistry expertise with drug delivery engineering knowledge, has among the tightest supply/demand ratios in the industry. Candidates with demonstrated experience in peptide oral bioavailability enhancement typically receive multiple competing offers within weeks of entering the market.
What to Watch in the Second Half of 2026
The next six months will produce meaningful clinical data readouts that could reshape the competitive picture. The key milestones to track include Novo Nordisk's COMET Phase III primary efficacy readout (expected Q3 2026), Eli Lilly's full Phase II oral tirzepatide analysis, and Structure Therapeutics' Phase II GSBR-1290 results.
The regulatory environment is also in focus. FDA has been actively engaging with sponsors developing oral GLP-1 programs through a structured advisory meeting process, and any formal agency guidance on the clinical evidence standards for oral-versus-injectable comparative claims would be highly market-moving.
For clinical staff and researchers considering career moves into the oral GLP-1 space, the current environment represents an unusually good entry point, programs are well-funded, the clinical endpoints are well-defined, and the commercial upside creates organizational commitment to timeline and budget that is not universal across therapeutic areas.
PeptideStaff covers clinical development hiring trends, regulatory developments, and market analysis across the peptide therapeutics industry. See PeptideStaff News for more coverage.
Topics
PeptideStaff Editorial Team
Healthcare Staffing Specialists
Collective expertise across clinical staffing, regulatory compliance, and peptide industry operations
Our editorial team combines backgrounds in healthcare recruitment, peptide research, and clinical operations to produce accurate, actionable staffing and industry guidance for peptide businesses.
Reviewed by the PeptideStaff Editorial Team, April 2026